Drugs / REGN17372
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07455851 | Mar 2026 → Sep 2033 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN17372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07455851 ↗ |
| Modality | Monoclonal antibody | “REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT07455851 ↗ |
| Target | CD28 | “REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT07455851 ↗ |
| Target | GPRC5D | “REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT07455851 ↗ |